Trial Profile

Front-line Venetoclax and Obinutuzumab Combination Followed by Venetoclax or Venetoclax and Zanubrutinib Combination in Patients With Residual Disease: a Minimal Residual Disease (MRD) Tailored Treatment for Young Patients With High-risk CLL

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Venetoclax (Primary) ; Zanubrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms VIS

15 Nov 2023 Planned End Date changed from 1 Jan 2027 to 1 Jul 2027.
15 Nov 2023 Planned primary completion date changed from 1 Nov 2025 to 1 May 2026.
15 Nov 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com